BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...Other deals have seen Takeda build out its vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

LigoCyte Pharmaceuticals, Takeda deal

...January. Sagent Advisors advised LigoCyte. Polsinelli Shugart was Takeda's legal advisor, while Cooley was LigoCyte's. LigoCyte Pharmaceuticals Inc....
BioCentury | Oct 5, 2012
Company News

Takeda to acquire LigoCyte

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire LigoCyte Pharmaceuticals Inc. (Bozeman, Mont.) for $60 million up front, plus...
BioCentury | Mar 17, 2011
Distillery Techniques

Technology: Drug platforms

...program. GlycoVaxyn AG's SD113 semisynthetic bioconjugate vaccine against Shigella dysenteriae has completed Phase I testing. LigoCyte Pharmaceuticals Inc....
BioCentury | Nov 15, 2010
Clinical News

Norovirus VLP intranasal vaccine: Phase I/II data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 27, 2010
Clinical News

Norovirus VLP intramuscular vaccine: Phase I started

...28 days apart in 98 healthy volunteers. The vaccine uses an MPL adjuvant from GlaxoSmithKline. LigoCyte Pharmaceuticals Inc....
BioCentury | May 17, 2010
Clinical News

Norovirus VLP vaccine: Phase I data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | May 17, 2010
Clinical News

Norovirus VLP vaccine: Phase I data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 14, 2009
Clinical News

Norovirus VLP vaccine: Phase I/II started

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 25, 2008
Tools & Techniques

Synthetic Dual-action Vaccines

...and a coauthor of the PNAS paper . Cutler is a founder of vaccine company LigoCyte Pharmaceuticals Inc....
...Institutions Mentioned Children's Hospital, New Orleans , New Orleans, La. GlycoVaxyn AG , Schlieren, Switzerland LigoCyte Pharmaceuticals Inc....
Items per page:
1 - 10 of 25
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...Other deals have seen Takeda build out its vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

LigoCyte Pharmaceuticals, Takeda deal

...January. Sagent Advisors advised LigoCyte. Polsinelli Shugart was Takeda's legal advisor, while Cooley was LigoCyte's. LigoCyte Pharmaceuticals Inc....
BioCentury | Oct 5, 2012
Company News

Takeda to acquire LigoCyte

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire LigoCyte Pharmaceuticals Inc. (Bozeman, Mont.) for $60 million up front, plus...
BioCentury | Mar 17, 2011
Distillery Techniques

Technology: Drug platforms

...program. GlycoVaxyn AG's SD113 semisynthetic bioconjugate vaccine against Shigella dysenteriae has completed Phase I testing. LigoCyte Pharmaceuticals Inc....
BioCentury | Nov 15, 2010
Clinical News

Norovirus VLP intranasal vaccine: Phase I/II data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 27, 2010
Clinical News

Norovirus VLP intramuscular vaccine: Phase I started

...28 days apart in 98 healthy volunteers. The vaccine uses an MPL adjuvant from GlaxoSmithKline. LigoCyte Pharmaceuticals Inc....
BioCentury | May 17, 2010
Clinical News

Norovirus VLP vaccine: Phase I data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | May 17, 2010
Clinical News

Norovirus VLP vaccine: Phase I data

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 14, 2009
Clinical News

Norovirus VLP vaccine: Phase I/II started

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....
BioCentury | Sep 25, 2008
Tools & Techniques

Synthetic Dual-action Vaccines

...and a coauthor of the PNAS paper . Cutler is a founder of vaccine company LigoCyte Pharmaceuticals Inc....
...Institutions Mentioned Children's Hospital, New Orleans , New Orleans, La. GlycoVaxyn AG , Schlieren, Switzerland LigoCyte Pharmaceuticals Inc....
Items per page:
1 - 10 of 25